HALO— HALOZYME THERAPEUTICS, INC.

MaterialsBiological Products, (No Diagnostic Substances)$11.7B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenues	$1.40B+37.6%	$1.02B+22.4%	$829.3M+25.6%	$660.1M
Cost of sales	$228.8M+43.5%	$159.4M-17.1%	$192.4M+38.1%	$139.3M
Amortization of intangibles	$76.7M+7.9%	$71.0M-3.7%	$73.8M+71.0%	$43.1M
Research and development	$81.5M+3.1%	$79.0M+3.5%	$76.4M+14.6%	$66.6M
Selling, general and administrative	$207.1M+34.2%	$154.3M+3.5%	$149.2M+3.9%	$143.5M
Impairment of intangible asset	$48.7M	$0	$0	—
Acquired in-process research and development expense	$284.9M	$0	$0	—
Total operating expenses	$927.6M+100.0%	$463.8M-5.7%	$491.7M+25.2%	$392.6M
Operating income	$469.0M-15.0%	$551.5M+63.4%	$337.6M+26.2%	$267.5M
Other income (expense)	—	—	—	—
Investment and other income, net	$21.5M-9.6%	$23.8M+45.6%	$16.3M+1459.9%	$1.0M
Inducement expense related to convertible notes	-$5.5M	$0	$0+100.0%	-$2.7M
Contingent liability fair value measurement gain	$0	$0-100.0%	$13.2M	$0
Interest expense	-$18.1M-0.2%	-$18.1M+3.6%	-$18.8M-10.7%	-$16.9M
Income before income tax expense	$466.9M-16.2%	$557.1M+59.9%	$348.3M+39.9%	$248.9M
Income tax expense	$150.0M+32.7%	$113.0M+69.4%	$66.7M+42.6%	$46.8M
Net income	$316.9M-28.6%	$444.1M+57.7%	$281.6M+39.3%	$202.1M
Basic (usd per share)	$2640.00-24.6%	$3500.00+64.3%	$2130.00+43.9%	$1480.00
Diluted (usd per share)	$2560.00-25.4%	$3430.00+63.3%	$2100.00+45.8%	$1440.00
Basic (in shares)	119.8M-5.5%	126.8M-3.9%	131.9M-3.6%	136.8M
Diluted (in shares)	123.9M-4.3%	129.4M-3.6%	134.2M-4.6%	140.6M
Royalties
Product sales, net
Revenues under collaborative agreements

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.